C12Y 304/2408
Membrane-type matrix metalloproteinase-1
Official title: Membrane-type matrix metalloproteinase-1 (3.4.24.80)
C12Y304/2408 (Membrane-type matrix metalloproteinase-1) appears on 7 US grants and 16 published applications in this corpus.
Search patents in C12Y- Granted patents
- 7
- Published applications
- 16
- Assignees
- 10
- Inventors
- 25
- Latest grant
- 5 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 1 |
| 2016 | 0 | 1 |
| 2017 | 0 | 0 |
| 2018 | 0 | 1 |
| 2019 | 1 | 2 |
| 2020 | 2 | 0 |
| 2021 | 0 | 2 |
| 2022 | 1 | 1 |
| 2023 | 0 | 1 |
| 2024 | 2 | 1 |
| 2025 | 0 | 2 |
| 2026 | 1 | 3 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Protease-cleavable substrates and methods of use thereof5 May 2026US 12,617,856 B2CytomX Therapeutics, Inc.
- Nanoparticles having molecules that bind or block PD-L1 and uses in treating cancer10 Sep 2024US 12,084,487 B2Emory University
- Fibrosis-inhibiting composition, cells producing same, and cell sheet comprising said cells9 Jan 2024US 11,866,483 B2KanonCure, Inc.
- Bicyclic peptide ligands and uses thereof8 Feb 2022US 11,241,473 B2BicycleTx Limited
- Bicyclic peptide ligands and uses thereof8 Dec 2020US 10,857,196 B2BicycleTx Limited
- Compositions targeting endothelial cells and uses thereof26 Mar 2026US 2026/0083866 A1President and Fellows of Harvard College
- Protease-cleavable moieties and methods of use thereof19 Feb 2026US 2026/0049148 A1CytomX Therapeutics, Inc.
- Protease-cleavable moieties and methods of use thereof12 Feb 2026US 2026/0042849 A1CytomX Therapeutics, Inc.
- Stroma penetrating therapeutic t-cell engager for cancer immunotherapy9 Oct 2025US 2025/0312465 A1Emory University
- Protease-cleavable substrates and methods of use thereof3 Jul 2025US 2025/0215095 A1CytomX Therapeutics, Inc.
Most cited
By later US patents
- Bicyclic peptide ligands and uses thereof20US 10,857,196 B2BicycleTx Limited · 2020
- Bicyclic peptide ligands and uses thereof17US 11,241,473 B2BicycleTx Limited · 2022
- Methods and compositions for reducing cardiac damage and other conditions2US 10,703,820 B2Tufts Medical Center, Inc. · 2020
- Inhibitors of endoglin activity for the treatment of fibrosis1US 10,214,590 B2Tufts Medical Center, Inc. · 2019